| Effect of targeted therapy and immunotherapy on advanced nonsmall‐cell lung cancer outcomes in the real world A Shokoohi, Z Al‐Hashami, S Moore, A Pender, SK Wong, Y Wang, ... Cancer Medicine 11 (1), 86-93, 2022 | 22 | 2022 |
| Discordance in PD-L1 scores on repeat testing of non-small cell lung carcinomas JR Naso, N Banyi, Z Al-Hashami, J Zhu, G Wang, DN Ionescu, C Ho Cancer Treatment and Research Communications 27, 100353, 2021 | 11 | 2021 |
| Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer R Rittberg, B Leung, Z Al-Hashami, C Ho Frontiers in Oncology 12, 1002385, 2022 | 5 | 2022 |
| Alternate pembrolizumab dosing interval in advanced NSCLC with PD-L1 TPS≥ 50%: 3 weekly compared to 6 weekly dosing L Jones, R Rittberg, B Leung, A Shokoohi, A Pender, S Wong, ... Current Oncology 29 (11), 8686-8692, 2022 | 4 | 2022 |
| Hepatocellular Carcinoma in Oman: An analysis of 284 cases K Al-Naamani, Z Al-Hashami, O Al-Siyabi, M Al-Moundri, B Al-Bahrani, ... Sultan Qaboos University Medical Journal 20 (3), e316, 2020 | 4 | 2020 |
| Lung cancer screening in the gulf: Rationale and recommendations SM Bennji, B Jayakrishnan, AH Al-Kindi, I Al-Jahdhami, Z Al-Hashami Annals of Thoracic Medicine 17 (4), 189-192, 2022 | 2 | 2022 |
| Impact of Tumor Location on Patient Outcomes in Small Bowel Cancers SY Irene, Z Al-Hashami, P Chapani, C Speers, JM Davies, HJ Lim, ... Clinical colorectal cancer 21 (2), 107-113, 2022 | 2 | 2022 |
| Pulmonary toxicities of immune check point inhibitors in the management of cancer: mini review B Jayakrishnan, M Al-Moundhri, I Burney, Z Al-Hashami, K Al-Bimani Advances in Respiratory Medicine 90 (3), 219-229, 2022 | 2 | 2022 |
| Real-World Outcomes of Stage IV NSCLC with PD-L1≥ 50% Treated with First-Line Pembrolizumab: Uptake of Second-Line Systemic Therapy R Rittberg, B Leung, A Shokoohi, A Pender, S Wong, Z Al-Hashami, ... Current Oncology 30 (6), 5299-5308, 2023 | 1 | 2023 |
| Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults B Leung, A Shokoohi, Z Al-Hashami, S Moore, A Pender, SK Wong, ... BMC cancer 23 (1), 360, 2023 | 1 | 2023 |
| Real world patient eligibility for second line lurbinectedin based treatment in small cell lung cancer: understanding epidemiology and estimating health care utilization R Rittberg, B Leung, Z Al-Hashami, C Ho Current Oncology 29 (12), 9744-9752, 2022 | 1 | 2022 |
| 1308P Effect of current treatment evolution in advanced NSCLC on overall survival in the real world A Shokoohi, Z Al-Hashami, S Moore, A Pender, S Wong, Y Wang, ... Annals of Oncology 31, S846, 2020 | 1 | 2020 |
| Management of a migrating feeding tube ZS Al-Hashami, K Al-Naamani, A Al-Kalbani Sultan Qaboos University Medical Journal 14 (3), 412-413, 2014 | 1 | 2014 |
| Challenges in managing chronic kidney disease with simultaneous renal transplant immunosuppressant induced buccal squamous cell carcinoma and gastric Burkitt's like lymphoma: A … SS Tajammul, S Maheshwari, J Munir, K Al-Farsi, A Allawati, ... Current Problems in Cancer: Case Reports 14, 100288, 2024 | | 2024 |
| The Prevalence and Patterns of Toxicity With Immune Checkpoint Inhibitors in Solid Tumors: A Real-World Experience From a Tertiary Care Center in Oman B Salman, NM AlWard, Z Al-Hashami, H Al-Sharqi, H Al-Sayegh, ... Cureus 15 (10), 2023 | | 2023 |
| Adenocarcinoma of lung presenting as diffuse interstitial lung disease B Jayakrishnan, I Burney, AH Osman, SM Bennji, Z Al-Hashami The Lancet Oncology 24 (7), e323, 2023 | | 2023 |
| Uptake of second-line anticancer therapy after first-line pembrolizumab in patients with stage IV non–small cell lung cancer with PD-L1> 50%: Comparison between clinical trials … R Rittberg, L Jones, B Leung, A Shokoohi, DN Ionescu, A Pender, R Yuan, ... Journal of Clinical Oncology 40 (28_suppl), 126-126, 2022 | | 2022 |
| Alternate pembrolizumab dosing interval in advanced NSCLC with PD-L1>/[50%: 3 weekly compared to 6 weekly dosing L Jones, R Rittberg, B Leung, A Shokoohi, A Pender, S Wong, ... ANNALS OF ONCOLOGY 33 (7), S1070-S1071, 2022 | | 2022 |
| EP14. 05-017 Real World Eligibility of Immune Checkpoint Inhibitors with Platinum-Doublet in Extensive Stage Small Cell Lung Cancer R Rittberg, B Leung, Z Al-Hashami, C Ho Journal of Thoracic Oncology 17 (9), S550-S551, 2022 | | 2022 |
| EP08. 02-089 Toxicity of Sequential Tyrosine Kinase Inhibitors After Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer L Jones, R Rittberg, B Leung, A Shokoohi, A Pender, S Wong, ... Journal of Thoracic Oncology 17 (9), S444, 2022 | | 2022 |
